Trading
Data
Solutions
Insights
About
Delfi Diagnostics is a biotechnology company with a mission to use its technology for early cancer detection. By developing AI and ML algorithms, Delfi Diagnostics offers predictive testing processes with the goal of maximizing patient survival rates. The company specializes in the detection of breast cancer and aims to help healthcare organizations minimize treatment toxicity with less-invasive treatments. Delfi Diagnostics was founded by Alessandro Leal and Victor Velculescu in 2019 and is headquartered in Baltimore, MD.
Delfi Diagnostics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Delfi Diagnostics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Delfi Diagnostics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 7/18/2022 | Series B | $225MM raised | $XXX.XX | $XXX.XX |
| 1/12/2021 | Series A | $95.97MM raised | $XXX.XX | $XXX.XX |
| 8/12/2019 | Series Seed | $5.5MM raised | $XXX.XX | $XXX.XX |
